The first US human trial using CRISPR to treat disease could kick off any day now. The trial, led by the University of Pennsylvania, will use the gene-editing tool to modify immune cells, prompting them to attack three different types of cancer.
Tagged With car-t
On Wednesday -- for only the second time -- the United States' Food and Drug Administration approved a cutting-edge therapy that genetically modifies a patient's blood cells in order to attack cancer. This time the therapy, known as CAR T-cell therapy, is designed to treat aggressive non-Hodgkin lymphoma.
On Wednesday, the US Food and Drug Administration approved a treatment that genetically modifies a patient's own blood cells in order to attack childhood leukaemia, a landmark decision opens the door for an era of FDA-sanctioned human gene modification.
This week marked a major milestone in medicine: On Wednesday, a US Food and Drug Administration panel unanimously recommended the approval of the first CAR-T therapy, a pioneering new cancer drug from Novartis that genetically engineers a patient's own white blood cells to recognise and attack the cancer cells invading their body.
Following the deaths of five patients, Juno Therapeutics has decided to pull the plug on an experimental cancer treatment that boosts the power of a patient's immune cells. The news comes just days after the company's rival, Kite Pharma, announced its success with a similar method, showing there's still hope for this potentially revolutionary gene therapy.